Page 59 - Read Online

Izkhakov et al. J Cancer Metastasis Treat 2021;7:24 https://dx.doi.org/10.20517/2394-4722.2021.24 Page 7 of 8

Copyright
© The Author(s) 2021.

REFERENCES
1. Davies L, Welch HG. Current thyroid cancer trends in the United States. JAMA Otolaryngol Head Neck Surg 2014;140:317-22. DOI
PubMed
2. La Vecchia C, Malvezzi M, Bosetti C, et al. Thyroid cancer mortality and incidence: a global overview. Int J Cancer 2015;136:2187-
95. DOI PubMed
3. Konturek A, Barczyński M, Stopa M, Nowak W. Trends in prevalence of thyroid cancer over three decades: a retrospective cohort
study of 17,526 surgical patients. World J Surg 2016;40:538-44. DOI PubMed PMC
4. Kitahara CM, Sosa JA. The changing incidence of thyroid cancer. Nat Rev Endocrinol 2016;12:646-53. DOI PubMed
5. Haugen BR, Alexander EK, Bible KC, et al. 2015 American thyroid association management guidelines for adult patients with thyroid
nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated
thyroid cancer. Thyroid 2016;26:1-133. DOI PubMed PMC
6. Filetti S, Durante C, Hartl D, et al. Thyroid cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann
Oncol 2019;30:1856-83. DOI PubMed
7. Mazzaferri EL, Young RL. Papillary thyroid carcinoma: a 10 year follow-up report of the impact of therapy in 576 patients. Am J Med
1981;70:511-8. DOI PubMed
8. Hall P, Lundell G, Holm LE. Mortality in patients treated for hyperthyroidism with iodine-131. Acta Endocrinol (Copenh)
1993;128:230-4. DOI PubMed
9. Franklyn JA, Maisonneuve P, Sheppard MC, Betteridge J, Boyle P. Mortality after the treatment of hyperthyroidism with radioactive
iodine. N Engl J Med 1998;338:712-8. DOI PubMed
10. Franklyn JA, Sheppard MC, Maisonneuve P. Thyroid function and mortality in patients treated for hyperthyroidism. JAMA
2005;294:71-80. DOI PubMed
11. Metso S, Jaatinen P, Huhtala H, Auvinen A, Oksala H, Salmi J. Increased cardiovascular and cancer mortality after radioiodine
treatment for hyperthyroidism. J Clin Endocrinol Metab 2007;92:2190-6. DOI PubMed
12. Collet TH, Gussekloo J, Bauer DC, et al. Subclinical hyperthyroidism and the risk of coronary heart disease and mortality. Arch Intern
Med 2012;172:799-809. DOI PubMed PMC
13. Sawin CT, Geller A, Wolf PA, et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N
Engl J Med 1994;331:1249-52. DOI PubMed
14. Klein Hesselink EN, Klein Hesselink MS, de Bock GH, et al. Long-term cardiovascular mortality in patients with differentiated
thyroid carcinoma: an observational study. J Clin Oncol 2013;31:4046-53. DOI PubMed
15. Yang L, Shen W, Sakamoto N. Population-based study evaluating and predicting the probability of death resulting from thyroid cancer
and other causes among patients with thyroid cancer. J Clin Oncol 2013;31:468-74. DOI PubMed
16. Izkhakov E, Keinan-Boker L, Barchana M, et al. Long-term all-cause mortality and its association with cardiovascular risk factors in
thyroid cancer survivors: an Israeli population-based study. BMC Cancer 2020;20:892. DOI PubMed PMC
17. Mercuro G, Panzuto MG, Bina A, et al. Cardiac function, physical exercise capacity, and quality of life during long-term thyrotropin-
suppressive therapy with levothyroxine: effect of individual dose tailoring. J Clin Endocrinol Metab 2000;85:159-64. DOI PubMed
18. Shargorodsky M, Serov S, Gavish D, Leibovitz E, Harpaz D, Zimlichman R. Long-term thyrotropin-suppressive therapy with
levothyroxine impairs small and large artery elasticity and increases left ventricular mass in patients with thyroid carcinoma. Thyroid
2006;16:381-6. DOI PubMed
19. Biondi B, Fazio S, Carella C, et al. Cardiac effects of long term thyrotropin-suppressive therapy with levothyroxine. J Clin Endocrinol
Metab 1993;77:334-8. DOI PubMed
20. Fazio S, Biondi B, Carella C, et al. Diastolic dysfunction in patients on thyroid-stimulating hormone suppressive therapy with
levothyroxine: beneficial effect of beta-blockade. J Clin Endocrinol Metab 1995;80:2222-6. DOI PubMed
21. Taillard V, Sardinoux M, Oudot C, et al. Early detection of isolated left ventricular diastolic dysfunction in high-risk differentiated
thyroid carcinoma patients on TSH-suppressive therapy. Clin Endocrinol (Oxf) 2011;75:709-14. DOI PubMed
22. Gazdag A, Nagy EV, Erdei A, et al. Aortic stiffness and left ventricular function in patients with differentiated thyroid cancer. J
Endocrinol Invest 2015;38:133-42. DOI PubMed
23. Abdulrahman RM, Delgado V, Hoftijzer HC, et al. Both exogenous subclinical hyperthyroidism and short-term overt hypothyroidism
affect myocardial strain in patients with differentiated thyroid carcinoma. Thyroid 2011;21:471-6. DOI PubMed
24. Abonowara A, Quraishi A, Sapp JL, et al. Prevalence of atrial fibrillation in patients taking TSH suppression therapy for management
of thyroid cancer. Clin Invest Med 2012;35:E152-6. DOI PubMed
25. Horne MK 3rd, Singh KK, Rosenfeld KG, et al. Is thyroid hormone suppression therapy prothrombotic? J Clin Endocrinol Metab
2004;89:4469-73. DOI PubMed
26. Pajamäki N, Metso S, Hakala T, et al. Long-term cardiovascular morbidity and mortality in patients treated for differentiated thyroid
cancer. Clin Endocrinol (Oxf) 2018;88:303-10. DOI PubMed
27. Suh B, Shin DW, Park Y, et al. Increased cardiovascular risk in thyroid cancer patients taking levothyroxine: a nationwide cohort study
in Korea. Eur J Endocrinol 2019;180:11-20. DOI PubMed
28. Izkhakov E, Meyerovitch J, Barchana M, Shacham Y, Stern N, Keinan-Boker L. Long-term cardiovascular and cerebrovascular